AMBEY — Ambey Laboratories Balance Sheet
0.000.00%
- IN₹1.10bn
- IN₹1.48bn
- IN₹1.31bn
Annual balance sheet for Ambey Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 5.12 | 2.89 | 10.2 | 11.6 | 17.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 73.8 | 90.8 | 37.9 | 190 | 422 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 200 | 243 | 275 | 484 | 865 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 155 | 241 | 242 | 271 | 382 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 446 | 559 | 576 | 794 | 1,272 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 219 | 216 | 203 | 310 | 396 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 525 | 369 | 340 | 479 | 509 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | -78.6 | 191 | 236 | 315 | 764 |
| Total Liabilities & Shareholders' Equity | 446 | 559 | 576 | 794 | 1,272 |
| Total Common Shares Outstanding |